Latest news with #TKA
Yahoo
5 days ago
- Business
- Yahoo
Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management
Series D led by Lightstone Ventures and ClavystBio, supported by leading global syndicate of new and existing investors; Additional venture debt funding led by HSBC Funds to advance ATX101 Phase 2b registration trial of post-surgical pain management in total knee replacement patients, data anticipated in Q4 2025 Joe Zakrzewski joins as Chairman of Allay Board of Directors Maruishi Pharmaceutical, Allay's partner in Japan, expands license territory to S. Korea and Taiwan SAN JOSE, Calif., June 05, 2025--(BUSINESS WIRE)--Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the completion of a $57.5M Series D financing round with leading global investors. Lightstone Ventures and ClavystBio co-led the Series D financing with participation by existing investors NEA, Arboretum Ventures, Vertex Growth, Vertex Ventures Healthcare, and Brandon Capital. New investors joining the round were IPD Capital, EDBI and SGInnovate, and HSBC Innovation Banking also provided additional venture debt financing to the Company. Allay also announced that Joe Zakrzewski, an experienced pharmaceutical executive, has been appointed Chairman of the Board of Directors, and Anselm Tan of ClavystBio will also join Allay's board, associated with the financing. Allay Therapeutics' Japanese partner Maruishi Pharmaceutical has expanded the territory of its license agreement to include South Korea and Taiwan, in addition to Japan. As part of the amendment to the license, Maruishi has also made an additional investment in Allay as part of the Series D financing. Maruishi is currently conducting a Phase I/II multi-center open-label safety study of ATX101 in Japan. Proceeds from the financing supports the Company's Phase 2b registration trial evaluating ATX101 for the treatment of post-surgical pain following total knee replacement (TKA) surgery and advances Allay's ultra-sustained platform of products for other unmet needs after painful surgeries. ATX101 is a novel investigational analgesic designed to provide extended pain relief after surgery, reducing the need for opioids and improving patient recovery. "Lightstone Ventures is pleased to be joined by a strong syndicate of biotechnology and medical device investors in the U.S. and Asia to support Allay with this fundraise to advance the Company's platform of products into pivotal clinical development. The Company is enrolling its Phase 2b registration trial ATX101 in the US for TKA surgeries and are expecting early completion of this trial in the coming months," stated Mike Carusi, Managing Partner at Lightstone Ventures. "It is rewarding to see Allay, which Lightstone Singapore helped to incubate alongside our partners at the Foundry, continue to grow and prosper." "With our recent breakthrough therapy designation (BTD) by FDA and constructive Type B meeting discussions held in March 2025, we have a clear roadmap to complete the ATX101 development program in TKA and are looking at additional indications and unmet needs in orthopedics, plastic surgery, anesthesiology and other soft tissue surgeries," stated Adam Gridley, President & CEO of Allay Therapeutics. "We believe the ATX platform of products driven by our teams in Singapore and the U.S. can help improve patient outcomes, reduce opioid use and improve function more rapidly than currently available therapies." "We are proud to support Allay as they advance best-in-class non-opioid solutions for patients suffering from pain and poor recovery outcomes after surgery. Allay exemplifies ClavystBio's mission to accelerate life sciences technologies from Singapore to the world," said Anselm Tan, Digital Health & MedTech Lead, ClavystBio. "ATX101 is one of several offerings in a pipeline driven by Singapore's R&D excellence, a strong collaboration among international teams, and a global syndicate of investors." Allay's Phase 2b registration trial of 200 participants undergoing total knee arthroplasty (replacement, or TKA surgery) is being conducted at multiple U.S. sites. The trial was initiated in February 2025 and is a three-arm, randomized, controlled study evaluating treatment with ATX101 1,500 mg versus placebo and a bupivacaine active comparator. A prior dose-ranging Phase 2b trial achieved clinically meaningful durable treatment effects with ATX101 versus standard-of-care bupivacaine based on pain intensity out to four weeks, with less use of opioids and meaningful improvement in functional activities up to 60 days following surgery. Based on those prior results, Allay's ATX101 product has received Breakthrough Therapy designation from the FDA. Results from the registration trial will be available in the fourth quarter of 2025 and a Phase 3 trial is planned for 2026. About Joe Zakrzewski:Mr. Zakrzewski has over 30 years of leadership experience in the biotechnology and pharmaceutical industry and has founded a number of biotechnology companies and been an inventor on numerous patents. He currently serves on the Board of Directors of multiple public & privately held companies. During his operating career he was Chairman and CEO of Amarin Pharmaceuticals, a Venture Partner with Orbimed, Chairman, President & Chief Executive Officer of Xcellerex, a privately held company sold to GE Healthcare, and COO of Reliant Pharmaceuticals, a privately held company sold to GSK plc. Prior to this, Mr. Zakrzewski served in various executive roles including global leadership for Business Development at Eli Lilly & Company. He received a BS in Chemical Engineering and an MS in Biochemical Engineering from Drexel University, and an MBA in Finance from Indiana University. About Lightstone VenturesLightstone Ventures is a global venture capital firm investing in biotech and medtech companies pioneering big ideas poised to transform patient outcomes. We were founded in 2012 to empower visionary entrepreneurs with the resources and operational guidance necessary to bring their innovative therapeutics and technologies to the patients who need them most. Our investment team has led deals resulting in 19 acquisitions and 20 initial public offerings over the last two decades. The firm has offices in Boston, Mass., Portola Valley, Calif., and Dublin, Ireland. For more information, please visit About ClavystBioClavystBio is a life sciences investor and venture builder established by Temasek to accelerate the commercialization of breakthrough ideas into health impact. We invest and partner with innovators, entrepreneurs and founders to launch and grow global companies from Singapore. Our focus spans therapeutics, digital health and medtech, with an emphasis on first-in-class science and technology. Our collaborative space, Node 1, provides plug-and-play spaces for ventures that have graduated from incubators to progress to their next milestones. By bringing startups together, we foster a vibrant and supportive community. Since our inception in 2022, ClavystBio has committed over US $220 million in investments in the life sciences sector. For more information, please visit About ATX101ATX101 is a novel investigational configuration of an approved, well-characterized, validated intracellular sodium ion channel blocker, bupivacaine, and a biopolymer that has been designed to provide weeks of pain relief following total knee arthroplasty (TKA, or replacement), a common orthopedic surgery. ATX101 has a high density of drug within its small footprint to allow for ultra-sustained analgesia. It is placed in minutes at the end of standard surgery to deliver its analgesic effect over weeks before eventually dissolving into water and carbon dioxide. The simple procedure does not require specialized training and is intended to replace the existing complex mix of analgesic products used for shorter-term pain management in the post-surgical setting. ATX101 is an investigational product that has not been approved by the U.S. Food and Drug Administration. About Allay TherapeuticsAllay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. Our proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable candidates to deliver pain relief within a targeted site over weeks: an order of magnitude greater than the longest-lasting pain treatments currently available. Our platform and vision were shaped by The Foundry incubator and Lightstone Venture's Singapore Fund. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore. Learn more at View source version on Contacts For further details, please contact:InvestorsAdam Mediaallay@ Sign in to access your portfolio
Yahoo
16-05-2025
- Business
- Yahoo
Monogram Technologies Inc (MGRM) Q1 2025 Earnings Call Highlights: FDA Clearance and Strategic ...
Release Date: May 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Monogram Technologies Inc (NASDAQ:MGRM) received FDA clearance for their embossed total TKA system, marking a significant milestone in the company's history. The company has a strong balance sheet with $13.3 million in cash and no traditional debt, providing financial stability. Monogram Technologies Inc (NASDAQ:MGRM) has reduced its monthly cash burn rate from $1.1-$1.2 million to $0.8 million, reflecting improved cost management. The company is set to initiate a groundbreaking multi-center clinical trial in India for autonomous saw-based robotic total knee surgeries. Monogram Technologies Inc (NASDAQ:MGRM) is actively showcasing its system to key opinion leaders and preparing for additional placements, indicating strong future growth potential. The company anticipates a slow and methodical initial rollout, which may delay immediate commercial traction. Monogram Technologies Inc (NASDAQ:MGRM) faces significant competition from established players like Stryker, which holds a dominant market share. The company requires additional capital to accelerate growth, indicating potential future funding needs. There are still technical and regulatory hurdles to overcome in both the US and India, which could impact timelines. The company's commercial success is heavily dependent on surgeon adoption and the ability to demonstrate the system's value proposition in real-world settings. Warning! GuruFocus has detected 9 Warning Signs with NSFDF. Q: Can you provide more detail on the timelines for technical and regulatory hurdles in the US and India? A: Unidentified_3: We expect to perform live patient surgeries in India within 90 business days, and the clinical trial system is on its way to India. In the US, our first placement is underway, and we anticipate it will be a reality in the operating room by Q3 2025. Q: How does Monogram plan to differentiate itself from Stryker's Mako system, particularly in terms of surgeon adoption? A: Unidentified_3: We aim to be competitive with Mako by focusing on accuracy, safety, and efficiency. Our system is designed to minimize surgeon fatigue and improve tensioning. We also have an AI-based preoperative pipeline for landmark identification, which we believe will be a small advantage over Mako. Q: What feedback have you received from key opinion leaders (KOLs) regarding the Monogram system? A: Unidentified_3: Initially, feedback was that the system was interesting but slow. Over time, we've improved speed and accuracy, and now surgeons are impressed with our progress. Surgeons familiar with Mako find our workflow intuitive. Q: Can you provide more details on the system enhancements being made? A: Unidentified_3: Since our FDA submission in July, we've made significant enhancements to the feed rate, end effector, blade, and software. These improvements allow for faster cutting, and we are conducting internal testing to ensure safety and performance. Q: How do you plan to manage the balance between a controlled rollout and the need for commercial traction and revenue growth? A: Unidentified_3: Our growth trajectory depends on capital access and strategic direction. We focus on high utilization of placed robots and aim to convert 100% of a surgeon's business to our system. We prioritize quality service and support for surgeons. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
06-03-2025
- Sport
- Yahoo
Why Skylar Walden knew a TSSAA basketball state championship game was inevitable for The King's Academy
COOKEVILLE — The King's Academy girls basketball coach Dante Turnipseed watched as a leaping, screaming mass of purple and white developed in front of him. He pumped both his fists, yelling "Let's go!" while shiny pom-poms flew through the air. It's been, in Turnipseed's words, a "roller coaster" ride for the Lions, a ride that none of them want to get off. And they won't have to just yet. TKA (27-7) beat Providence Christian 57-36 in Thursday's TSSAA basketball Division II-A state semifinal at the Hooper Eblen Center and will face either Webb School - Bell Buckle or University School of Jackson in Saturday's championship game that will start at 11 a.m. The Lions, whose first and only title game appearance came in 2020, reached the semifinals in 2023 and 2024 but lost both games. "It's like a turning point," said sophomore Skylar Walden. "Winning a game up here means so much. This is our third year and we're finally getting it done." Walden said she knew TKA was going to win at halftime. The Lions led 27-15, hardly out of range for a comeback, but their leading scorer sensed the momentum was on their side. To Walden, PCA (23-7) seemed devoid of energy, almost dead. Part of that came down to how the first half ended. With seconds remaining, Walden drew a foul on a 3-point attempt and went 3-for-3 at the line. Those free throws — her first points of the game — were the catalysts for 21 more points in the second half. They were hard-earned points, as Providence Christian tried to take away what Walden does best. PCA coach Tara James schemed to run Walden, who came into Thursday having hit 105 threes at nearly 40% for the season, off the 3-point line. PCA fought hard to get over screens and close the little pockets from which Walden could let it fly. With her favorite shots guarded up, Walden simply decided not to attempt them. She finished with 24 points — eight above her season average — on 7-of-11 shooting, driving the lane with great success while only attempting two threes and not hitting her first until deep into the fourth quarter. "I was trying not to force anything," Walden said. "If I can get a layup, they'll start crashing in and we can get other threes. I was just trying to take what they were giving me." Wofford signee Brady Branam and Adit Koul worked off Walden's gravity and combined for 19 points, mostly in the paint, while TKA separated itself at the free throw line too. The Lions only committed six fouls as a team and went 15-of-20 from the foul line, while PCA made just one trip there for the game. MORE: Colin Brown, Trey Thompson each score over 30 to lead Greeneville in Knoxville area top performers Defending without fouling was an emphasis for Turnipseed, who wanted to speed up the game and take advantage of PCA miscues rather than selling out for steals. That strategy resulted in 19 turnovers, even as TKA wasn't necessarily trying to force them. "I told them, 'Let's not try to foul them, let's try to run them to death,' " Turnipseed said. "... If they fumble it, then we can get it, but let's not foul and make them get easy points." One month ago, the Lions were reeling, having lost their last two games in the District 1 tournament. Now, they're a win away from bringing a gold ball back to Seymour. "The girls just bought in and said, 'Hey, this is not it,' Turnipseed said. "We put district behind us, and we don't look back in the rearview mirror." Jacob Shames can be reached by email at jshames@ and on Twitter @Jacob_Shames. This article originally appeared on Knoxville News Sentinel: TSSAA basketball tournament: The King's Academy in Division II-A state final
Associated Press
26-02-2025
- Business
- Associated Press
Monogram Technologies Provides Regulatory Update on mBôs TKA System and Clinical Trial Preparation in India
Company has Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Investigator Meeting and Clinical Trial Training Held at the Shalby Hospital in Ahmedabad, India AUSTIN, TX / ACCESS Newswire / February 26, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ('Monogram' or the 'Company'), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update regarding its 510(k) premarket filing submission to the U.S. Food and Drug Administration ('FDA') for the Company's mBôs TKA System. The Company has completed all supplemental testing and submitted its formal response to the U.S. Food and Drug Administration (FDA) regarding the Additional Information Request (AIR) received on September 30, 2024. The Company does not currently anticipate further requests for information from the agency. Assuming a favorable decision by the FDA following receipt of the AIR, the next communication from them is anticipated to be a clearance decision for the mBôs™ Total Knee Arthroplasty (TKA) System. If granted, that would enable commercialization and sales of the TKA system in the United States. In August 2024, Monogram announced a strategic collaboration with Shalby Limited (NSE:SHALBY) ('Shalby'), a global multi-specialty hospital chain and one of India's leading orthopedic hospital groups, to conduct a multicenter clinical trial to evaluate the safety and effectiveness of the mBôs TKA System. In January 2025, the Company shipped a robot to support clinical trial training. The robot was successfully shipped as planned, and an Investigator Meeting was conducted at a Shalby Hospital in Ahmedabad, India, from January 31 to February 1, 2025. The meeting was organized by Reliance Life Sciences, a subsidiary of Reliance Industries, and attended by principal investigators, multiple surgeons, and staff. The purpose of the meeting was to review study protocols, regulatory requirements, and operational procedures. Reliance Life Sciences, a Reliance Group company-one of India's largest private sector companies-is responsible for managing the regulatory submission and communications for the clinical trial in India. As the regulatory sponsor, Reliance Life Sciences is overseeing the submission process and engagement with India's regulatory authorities. Monogram has submitted its system for regulatory clearance to run the clinical trial and will provide updates as they occur. While regulatory timelines can be variable, the Company remains confident in its submission and the strength of its strategic partnerships with Reliance Life Sciences and Shalby to support the process. 'The Investigator Meeting was a successful milestone in the preparation for Monogram's clinical trial,' said Dr. Ajaykumar Yadav, Associate Vice President and Group Head of Clinical Research at Reliance Life Sciences. 'Bringing together key stakeholders, the meeting provided an opportunity for in-depth discussions on study protocols and a demonstration of the mBôs technology, reinforcing the collaborative approach to this clinical trial. Monogram has submitted a strong and comprehensive application, and we continue to support the regulatory process as expected. Reliance Life Sciences remains committed to advancing innovation in healthcare and looks forward to contributing to the successful execution of this study.' Monogram team in Ahmedabad, India, with various stakeholders for clinical trial Investigator Meeting from Jan 31 to Feb 1, 2025. Monogram continues to refine and enhance its next-gen technology in parallel with its regulatory and clinical trial preparations. The most significant advancement has been to the cutting system, which has facilitated an approximately 300% increase in feed rate. A video demonstrating these next-gen improvements is available below. Dr. Douglas Unis, Monogram's Chief Medical Officer, commented, 'The latest advancements in Monogram's robotic system are a game changer. The new cutting system enables cutting speeds that are becoming competitive with manual surgery while maintaining the accuracy and functionality expected from robotic-assisted procedures. The performance is truly remarkable for a completely hands-free, unconstrained autonomous system. With these improvements, we are on track to deliver one of the most impressive robotic solutions on the market today.' The Company remains focused on developing a multi-application robotic system that is time-competitive with manual surgery without compromising accuracy or safety. Monogram continues to refine its technology to improve system performance and usability as it progresses toward commercialization. The Company believes its approach to active robotic cutting offers a unique value proposition and remains committed to innovation in orthopedic robotics. 'We have completed all proposed testing with what we view to be favorable results and we remain focused on developing a robotic platform that surgeons will want to use,' said Ben Sexson, CEO. 'Our research shows that safety and uncompromised speed are the top priorities for surgeons. We have always believed that an autonomous system could be optimized to be competitive with manual surgical times. I feel confident we are starting to get there. Like our shareholders, we are eager to bring this vision to the operating room. 'We have built a system that we believe has the potential to disrupt the market. Our thesis is that fast, accurate, unconstrained autonomous cutting, eventually in many clinical applications, will help drive continued adoption of robotics. Our technology has undergone rigorous and extensive testing, and we have made every effort to try and ensure our system meets the highest standards. 'What we have accomplished-with fewer than 30 full-time employees-is a testament to the dedication and expertise of our team. I could not be prouder of what our small and highly dedicated team has achieved.' About Monogram Technologies Inc. Monogram Technologies (NASDAQ:MGRM) is an AI-driven robotics company focused on improving human health, with an initial focus on orthopedic surgery. The Company is developing a product solution architecture to enable patient-optimized orthopedic implants at scale by combining 3D printing, advanced machine vision, AI and next-generation robotics. Monograms mBôs precision robotic surgical system is designed to autonomously execute optimized paths for high-precision insertion of its FDA-cleared mPress press-fit implants. The goal is well balanced, better-fitting bone sparing knee replacements. The Company initially intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation necessary for reconstructive joint replacement procedures. Other clinical and commercial applications for the mBôs with mVision navigation are also being explored. Monogram has obtained FDA clearance for mPress implants and applied for 510(k) clearance for its robotic products. The Company is required to obtain FDA clearance before it can market its products. Monogram cannot estimate the timing or assure the ability to obtain such clearances. The Company believes that its mBôs precision robotic surgical assistants, which combine AI and novel navigation methods (mVision), will enable more personalized knee implants for patients, resulting in well balanced better-fitting knee replacements with bone sparing implants. Monogram anticipates that there may be other clinical and commercial applications for its navigated mBôs precision robot and mVision navigation. To learn more, visit Forward-Looking Statements This press release may contain 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties.. Forward-looking statements, other than statements of historical fact, are highly likely to be affected by other unknowable future events and conditions, including elements of the future that are or are not under our control, and that the Company may or may not have considered; accordingly, such statements cannot be guarantees or assurances of any aspect of future performance. Actual developments and results are highly likely to vary materially from any forward-looking statements as a result of a number of factors, including those described in the prospectus and the Company's other filings with the SEC. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release. Executive Vice President MZ North America
Yahoo
14-02-2025
- Business
- Yahoo
Is There An Opportunity With thyssenkrupp AG's (ETR:TKA) 33% Undervaluation?
The projected fair value for thyssenkrupp is €7.01 based on 2 Stage Free Cash Flow to Equity thyssenkrupp's €4.70 share price signals that it might be 33% undervalued Analyst price target for TKA is €5.13 which is 27% below our fair value estimate How far off is thyssenkrupp AG (ETR:TKA) from its intrinsic value? Using the most recent financial data, we'll take a look at whether the stock is fairly priced by taking the expected future cash flows and discounting them to their present value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Believe it or not, it's not too difficult to follow, as you'll see from our example! We generally believe that a company's value is the present value of all of the cash it will generate in the future. However, a DCF is just one valuation metric among many, and it is not without flaws. For those who are keen learners of equity analysis, the Simply Wall St analysis model here may be something of interest to you. View our latest analysis for thyssenkrupp We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate: 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF (€, Millions) -€433.7m -€830.0m €273.7m €306.1m €332.4m €353.5m €370.4m €383.9m €395.1m €404.4m Growth Rate Estimate Source Analyst x2 Analyst x1 Analyst x1 Est @ 11.82% Est @ 8.60% Est @ 6.35% Est @ 4.77% Est @ 3.67% Est @ 2.89% Est @ 2.35% Present Value (€, Millions) Discounted @ 6.8% -€406 -€727 €224 €235 €239 €238 €233 €226 €218 €209 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = €689m The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (1.1%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.8%. Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = €404m× (1 + 1.1%) ÷ (6.8%– 1.1%) = €7.1b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= €7.1b÷ ( 1 + 6.8%)10= €3.7b The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is €4.4b. The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of €4.7, the company appears quite good value at a 33% discount to where the stock price trades currently. Remember though, that this is just an approximate valuation, and like any complex formula - garbage in, garbage out. Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at thyssenkrupp as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.8%, which is based on a levered beta of 1.327. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. Strength Debt is not viewed as a risk. Weakness Dividend is low compared to the top 25% of dividend payers in the Metals and Mining market. Opportunity Expected to breakeven next year. Has sufficient cash runway for more than 3 years based on current free cash flows. Good value based on P/S ratio and estimated fair value. Threat Paying a dividend but company is unprofitable. Whilst important, the DCF calculation ideally won't be the sole piece of analysis you scrutinize for a company. The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. What is the reason for the share price sitting below the intrinsic value? For thyssenkrupp, we've put together three pertinent elements you should consider: Risks: To that end, you should be aware of the 1 warning sign we've spotted with thyssenkrupp . Future Earnings: How does TKA's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing! PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the XTRA every day. If you want to find the calculation for other stocks just search here. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
